Date published: 2025-12-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

UBLCP1 Activators

UBLCP1 activators encompass a diverse array of chemical compounds that enhance its functional activity through various signaling pathways and cellular processes. The activation of adenylate cyclase by certain molecules raises intracellular cAMP levels, which in turn activates protein kinase A (PKA). PKA is known to phosphorylate a wide range of substrates and could influence UBLCP1, a phosphatase, by altering its substrate availability or modifying its regulatory subunits, thus indirectly increasing UBLCP1 activity. In a similar vein, substances that hinder the breakdown of cAMP or those that mimic its action can also augment PKA activity, thereby potentially affecting UBLCP1's phosphatase activity. Some activators function by inhibiting protein phosphatases such as PP1 and PP2A. This inhibition can shift the cellular phosphoprotein equilibrium, potentially resulting in an indirect enhancement of UBLCP1 activity due to changes in the phosphorylation states of proteins that interact with or regulate UBLCP1.

Other activators target different kinases or phosphatases, modulating signaling cascades that UBLCP1 might be involved in. For instance, the inhibition of Syk kinase or GSK-3 can lead to alterations in downstream signaling pathways, which could indirectly heighten the activity of UBLCP1. Additionally, certain kinase inhibitors can impact kinase-dependent signaling pathways, possibly resulting in increased UBLCP1 activity through a compensatory mechanism or by alteration of its interaction network. Conversely, direct activation of protein kinase C (PKC) through specific molecules could stimulate pathways that ultimately lead to an upregulation of UBLCP1 activity. These pathways often involve complex signaling cascades, and the net effect of PKC activation could be the amplification of signals that converge on UBLCP1. Lastly, molecules that activate specific cell surface receptors influence intracellular signaling networks, which may include pathways directly or indirectly involving UBLCP1, thus potentially facilitating its activation.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$76.00
$150.00
$725.00
$1385.00
$2050.00
73
(3)

Activates adenylate cyclase, increasing cAMP levels. UBLCP1 is a phosphatase that may be regulated by PKA, which is activated by cAMP.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$159.00
$315.00
$598.00
34
(1)

Non-specific inhibitor of phosphodiesterases, prevents cAMP degradation, potentially enhancing PKA activity and UBLCP1 regulation.

Dibutyryl-cAMP

16980-89-5sc-201567
sc-201567A
sc-201567B
sc-201567C
20 mg
100 mg
500 mg
10 g
$45.00
$130.00
$480.00
$4450.00
74
(7)

Membrane-permeable cAMP analog that activates PKA, possibly influencing UBLCP1 activity through phosphorylation events.

Okadaic Acid

78111-17-8sc-3513
sc-3513A
sc-3513B
25 µg
100 µg
1 mg
$285.00
$520.00
$1300.00
78
(4)

Inhibitor of protein phosphatases PP1 and PP2A, which could alter UBLCP1 activity by changing the phosphoprotein landscape.

Calyculin A

101932-71-2sc-24000
sc-24000A
10 µg
100 µg
$160.00
$750.00
59
(3)

Inhibits protein phosphatases like Okadaic Acid, potentially modifying UBLCP1 activity through indirect regulation of substrates.

Cantharidin

56-25-7sc-201321
sc-201321A
25 mg
100 mg
$81.00
$260.00
6
(1)

Inhibits protein phosphatases PP1 and PP2A, possibly affecting UBLCP1 activity by altering the balance of phosphatase activities.

Piceatannol

10083-24-6sc-200610
sc-200610A
sc-200610B
1 mg
5 mg
25 mg
$50.00
$70.00
$195.00
11
(2)

Inhibits Syk kinase, potentially modifying signaling pathways that UBLCP1 is involved in, leading to increased UBLCP1 activity.

Lithium

7439-93-2sc-252954
50 g
$214.00
(0)

Inhibits GSK-3, which may impact pathways regulating UBLCP1, leading to enhanced activity of UBLCP1.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$103.00
$237.00
36
(1)

PKC inhibitor, could alter PKC-mediated signaling pathways that affect UBLCP1 activity.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Broad-spectrum kinase inhibitor, could modify kinase-dependent signaling pathways involved in UBLCP1 regulation.